TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7104161
Drug: Oral meptazinol
Normalized name: meptazinol
DrugBank: Meptazinol (DB13478)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral meptazinol (200 mg)
Study: 25885012
Drug: Psychostimulant plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychostimulant plus parent training plus placebo (basic treatment)
Study: 25885012
Drug: Psychostimulant plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychostimulant plus parent training plus risperidone (augmented treatment)
Study: 24035403
Drug: LY2140023 (20mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: LY2140023 (20mg twice daily)
Study: 21926861
Drug: Protocol B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protocol B (80 kV with 100 mL of contrast material)
Study: 21926861
Drug: Protocol A
Normalized name: Olay Professional Acne Protocol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protocol A (standard 120 kV with 150 mL of contrast material)
Study: 19194995
Drug: Atomoxetine (ATX)
DrugBank: Atomoxetine (DB00289)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atomoxetine (ATX) 40-100 mg
Study: 9222944
Drug: Intravenous saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous saline infusion
Study: 16304280
Drug: Hypertonic saline
Normalized name: ENTSOL Hypertonic Saline Nasal Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypertonic saline solution challenge
Study: 10598692
Drug: Dorzolamide-timolol combination
Normalized name: dorzolamide / timolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dorzolamide-timolol combination (2.0% dorzolamide and 0.5% timolol) administered twice daily plus placebo once daily
Study: 10598692
Drug: 2.0% Dorzolamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.0% Dorzolamide administered three times daily plus placebo once daily
Study: 10598692
Drug: 0.5% Timolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% Timolol administered twice daily plus placebo once daily
Study: 1662636
Drug: Azithromycin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin (500 mg single dose on day 1, followed by 250 mg once-daily on days 2-5)
Study: 1662636
Drug: Cefaclor (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefaclor (500 mg t.i.d. for 10 days)
Study: 29433850
Drug: Lenvatinib (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lenvatinib (12 mg/day for bodyweight ≥60 kg or 8 mg/day for bodyweight <60 kg)
Study: 29433850
Drug: Sorafenib (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sorafenib (400 mg twice-daily in 28-day cycles)
Study: 11172833
Drug: Cetrorelix acetate
Normalized name: Cetrorelix Acetate
DrugBank: Cetrorelix (DB00050)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cetrorelix acetate 3 mg
Study: 11899964
Drug: Cr supplements
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cr supplements as brewer's yeast
Study: 11899964
Drug: Cr supplements
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cr supplements as CrCl3
Study: 11899964
Drug: Cr supplements
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cr supplements (both types)
Study: 11899964
Drug: Subjects responding
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects responding to Cr supplement
Study: 10078403
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose mivacurium (0.08 mg.kg‐1)
Study: 10078403
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose succinylcholine (0.5 mg.kg‐1)
Study: 7723664
Drug: Overnight branched-chain
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overnight branched-chain amino acid (BCAA) infusion
Study: 21724263
Drug: Intravitreal 1.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal 1.25 mg/0.05 ml bevacizumab injection 1 to 14 days before PPV (Group 1)
Study: 21724263
Drug: Intravitreal 1.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal 1.25 mg/0.05 ml bevacizumab injection at the end of PPV (Group 2)
Study: 21724263
Drug: No IVB
Approvals — FDA: no, EMA: no, PMDA: no
Description: No IVB injection (Group 3)
Study: 18173006
Drug: Lactofem (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactofem (1 capsule and 2 ml of gel every third day for one month)
Study: 18173006
Drug: Metronidazole (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metronidazole (1 g daily for 7 days)
Study: 14716182
Drug: Intravaginal estriol
Normalized name: Estriol
DrugBank: Estriol (DB04573)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravaginal estriol (1 mg once daily for 2 weeks, then 2 ovules once weekly for 6 months)
Study: 14716182
Drug: Inert placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inert placebo vaginal suppositories
Study: 9192511
Drug: Calcitriol (0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcitriol (0.25 microg twice daily)
Study: 11549632
Drug: Calcium (500
Normalized name: calcium gluconate 45 mg calcium (500 mg) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium (500 mg twice daily)
Study: 7509244
Drug: Acetorphan (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetorphan (300 mg)
Study: 7509244
Drug: Cilazapril (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cilazapril (5 mg)
Study: 3044506
Drug: Budesonide 200
Normalized name: budesonide 200 mcg/inh inhalation powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide 200 micrograms (one puff) given twice daily during 6-week treatment period
Study: 3044506
Drug: Placebo (one
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (one puff) given twice daily during 6-week control period
Study: 12545290
Drug: Nimodipine 30
Normalized name: nimodipine 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nimodipine 30 mg twice a day
Study: 8872871
Drug: IV 0.5
Normalized name: Immphentiv 0.5 MG per 5 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV 0.5 mg scopolamine (SCO)
Study: 6427609
Drug: Cimetidine (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine (300 mg) four times daily
Study: 31454347
Drug: Integration of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Integration of a preventive nutrition package including age-appropriate behavior change communication (BCC) and small-quantity lipid-based nutrient supplements (SQ-LNS)
Study: 29548623
Drug: RUSF-v (fortified
Approvals — FDA: no, EMA: no, PMDA: no
Description: RUSF-v (fortified with arginine and citrulline, daily chloroquine 3 mg/kg)
Study: 29548623
Drug: RUSF-b (basic
Approvals — FDA: no, EMA: no, PMDA: no
Description: RUSF-b (basic formulation, weekly chloroquine 150 mg or 225 mg)
Study: 22762844
Drug: Edaravone 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Edaravone 20 mg
Study: 22762844
Drug: Edaravone 30
Normalized name: edaravone 30 MG in 100 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Edaravone 30 mg (single dose)
Study: 22762844
Drug: Edaravone 60
Normalized name: edaravone 60 MG in 100 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Edaravone 60 mg
Study: 22762844
Drug: Edaravone 30
Normalized name: edaravone 30 MG in 100 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Edaravone 30 mg (repeated dosing)
Study: 11120927
Drug: Maternal viral
Normalized name: undecylenate
DrugBank: Undecylenic acid (DB11117)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Maternal viral RNA levels >43,000 copies/mL
Study: 9834048
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg zaleplon
Study: 10849244
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg zolpidem
Study: 2678768
Drug: Cefoxitin (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefoxitin (5 doses beginning 0.5‐1.0 hour preoperatively)
Study: 31574343
Drug: Licorice syrup
Approvals — FDA: no, EMA: no, PMDA: no
Description: Licorice syrup (5 cc, twice a day for 6 months)
Study: 31574343
Drug: Placebo syrup
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo syrup (5 cc, twice a day for 6 months)
Study: 30612487
Drug: Cognitive Behavioural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioural Therapy for insomnia (CBTi)
Study: 26924011
Drug: Early oral
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early oral feeding plus domperidone
Study: 19742431
Drug: Adjunctive therapies
Normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjunctive therapies
Study: 17617280
Drug: Amlodipine 5
Normalized name: amlodipine 5 MG
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amlodipine 5 mg + valsartan 320 mg
Study: 17617280
Drug: Amlodipine 10
Normalized name: amlodipine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine 10 mg + valsartan 160 mg
Study: 17617280
Drug: Amlodipine 10
Normalized name: amlodipine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine 10 mg + valsartan 320 mg
Study: 20234783
Drug: Amlodipine monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine monotherapy
Study: 12611200
Drug: Both medicines
Normalized name: Percy Medicine
DrugBank: Bismuth subsalicylate (DB01294)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Both medicines
Study: 31764804
Drug: Integrated traditional
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Integrated traditional Chinese and Western medicine treatment group
Study: 29077816
Drug: Chewing gum
Normalized name: Chewing Gum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chewing gum (chlorophyll flavour, with 2.1 g carbohydrate)
Study: 22530879
Drug: Glucose drink
Normalized name: Dextrose 15 GM Oral Solution [RELION GLUCOSE DRINK]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose drink (1.0 g·kg(‐1) body weight)
Study: 19304119
Drug: 5 mg/day
Normalized name: Lyllana 0.05 MG/Day Transdermal Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg/day enalapril plus 80 mg/day valsartan (combination group)
Study: 19304119
Drug: 10 mg/day
Normalized name: Adlarity 10 MG/Day Weekly Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg/day enalapril (control group)
Study: 17805035
Drug: Alendronate (Fosamax)
Normalized name: alendronate
DrugBank: Alendronic acid (DB00630)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alendronate (Fosamax) administered for at least 6 months
Study: 15657405
Drug: Individualized dosing
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Individualized dosing of docetaxel (mean 58.1 mg/m2, range 37.4 to 76.4 mg/m2)
Study: 15657405
Drug: BSA-based dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: BSA-based dosing of docetaxel (60 mg/m2)
Study: 15657405
Drug: Individualized dosing
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Individualized dosing of docetaxel
Study: 15657405
Drug: BSA-based dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: BSA-based dosing of docetaxel
Study: 11282808
Drug: Citalopram (20-60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citalopram (20-60 mg)
Study: 1974071
Drug: Alpidem 25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alpidem 25 mg
Study: 1974071
Drug: Alpidem 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alpidem 100 mg
Study: 1974072
Drug: Lorazepam 2
Normalized name: lorazepam 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lorazepam 2 mg (verum)
Study: 25947329
Drug: LMWH enoxaparin
Normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
Approvals — FDA: no, EMA: no, PMDA: no
Description: LMWH enoxaparin 40 mg subcutaneously once daily plus standard pregnancy surveillance
Study: 23391727
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual (TAU, antidepressant medication) (n = 50)
Study: 19766640
Drug: Delayed-release mesalamine
Normalized name: mesalamine Delayed Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed-release mesalamine 4.8 g/day
Study: 19766640
Drug: Delayed-release mesalamine
Normalized name: mesalamine Delayed Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed-release mesalamine 2.4 g/day
Study: 16494585
Drug: Placebo (COX-2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (COX-2 inhibitors)
Study: 16494585
Drug: Esomeprazole 20
Normalized name: esomeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esomeprazole 20 mg (COX-2 inhibitors)
Study: 16494585
Drug: Esomeprazole 40
Normalized name: esomeprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esomeprazole 40 mg (COX-2 inhibitors)
Study: 1097977
Drug: Oral prostaglandin
Normalized name: Prostaglandin D2
DrugBank: Prostaglandin D2 (DB02056)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral prostaglandin E2 (PGE2)
Study: 6145639
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of oxytocin (Oxy)
Study: 25496023
Drug: Vitamin A
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin A supplementation (25,000 IU retinyl palmitate daily for 4 months)
Study: 21809148
Drug: Ketamine 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine 0.5 mg/kg bolus
Study: 16882622
Drug: Radiotherapy (RT)
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Radiotherapy (RT) with a mean dose of 32 Gy (range 30 - 46 Gy)
Study: 16882622
Drug: Radiotherapy (RT)
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Radiotherapy (RT) with doses of 35 - 46 Gy
Study: 11329782
Drug: Amrubicin 30
Normalized name: Valrubicin
DrugBank: Valrubicin (DB00385)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amrubicin 30 mg/day
Study: 11329782
Drug: Amrubicin 60
Normalized name: Valrubicin
DrugBank: Valrubicin (DB00385)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amrubicin 60 mg/day
Study: 11329782
Drug: Amrubicin 90
Normalized name: Valrubicin
DrugBank: Valrubicin (DB00385)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amrubicin 90 mg/day
Study: 11329782
Drug: Amrubicin 120
Normalized name: Valrubicin
DrugBank: Valrubicin (DB00385)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amrubicin 120 mg/day
Study: 8302687
Drug: Soft gelatin
Normalized name: Norvir Soft Gelatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soft gelatin capsule (reference)
Study: 8302687
Drug: Oral solution
Normalized name: Oral Solution
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral solution under fasting conditions
Study: 8302687
Drug: Oral solution
Normalized name: Oral Solution
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral solution mixed with orange juice
Study: 3090588
Drug: beta blocker
Normalized name: Beta blocker
Approvals — FDA: no, EMA: no, PMDA: no
Description: beta blocker (atenolol or propranolol)
Study: 28474088
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg IV dexamethasone
Study: 27321368
Drug: 1.5 g
Normalized name: Vaporizer Vicks 1.5 gal
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 g ACCS100 daily for 3 months
Study: 27321368
Drug: 3 g
Normalized name: Molds 3 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 g ACCS100 daily for 3 months
Study: 24730717
Drug: Low-dose lithium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose lithium carbonate for 4 years
Study: 8846930
Drug: Transdermal 17
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal 17 beta Estradiol (Estraderm TTS 100 plasters) for 24 weeks, with Chlormadinon 2 mg from day 16 to 28 of the fourth cycle
Study: 1298792
Drug: Step-back/ultrasound preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Step-back/ultrasound preparation
Study: 1298792
Drug: Step-back preparation
Normalized name: Pep-Back
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Step-back preparation
Study: 6375802
Drug: Cefuroxime (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefuroxime (1.5 g intravenous injection)
Study: 24786356
Drug: Evacetrapib monotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evacetrapib monotherapy 30 mg
Study: 24786356
Drug: Evacetrapib monotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evacetrapib monotherapy 100 mg
Study: 24786356
Drug: Evacetrapib monotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evacetrapib monotherapy 500 mg
Study: 24786356
Drug: Evacetrapib 100
Normalized name: Evacetrapib
DrugBank: Evacetrapib (DB11655)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evacetrapib 100 mg in combination with atorvastatin 10 mg
Study: 18633023
Drug: Overall antiemetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall antiemetic administration
Study: 22469445
Drug: Rescue medication
Normalized name: ALLERGENIC EXTRACT, MEADOW FESCUE POLLEN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rescue medication use
Study: 12594633
Drug: Tafenoquine 25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tafenoquine 25 mg/week
Study: 12594633
Drug: Tafenoquine 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tafenoquine 50 mg/week
Study: 12594633
Drug: Tafenoquine 100
Normalized name: tafenoquine 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tafenoquine 100 mg/week
Study: 12594633
Drug: Tafenoquine 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tafenoquine 200 mg/week
Study: 12594633
Drug: Mefloquine 250
Normalized name: mefloquine 250 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mefloquine 250 mg/week
Study: 3939672
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg b.i.d. of terfenadine
Study: 3939672
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg t.i.d. of chlorpheniramine (active control)
Study: 27733098
Drug: Eyedropper doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eyedropper doses of phenylephrine and tropicamide
Study: 22337156
Drug: Enhanced format
Normalized name: formate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enhanced format consent documents (printed on 20-pound, cream-colored bond paper and presented in a blue folio)
Study: 12034516
Drug: Oral tibolone
Normalized name: TIBOLONE
DrugBank: Tibolone (DB09070)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tibolone 2.5 mg per day
Study: 12034516
Drug: Cyclic combined
Normalized name: cyclic AMP
DrugBank: Cyclic adenosine monophosphate (DB02527)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclic combined regimen of transdermal oestrogen and progestogen
Study: 8869019
Drug: Integrelin (glycoprotein
Approvals — FDA: no, EMA: no, PMDA: no
Description: Integrelin (glycoprotein IIb/IIIa receptor inhibitor)
Study: 8869019
Drug: Higher doses
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher doses of integrelin
Study: 373100
Drug: 250 mg
Normalized name: rutin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg tienilic acid
Study: 388400
Drug: 125 mg
Normalized name: niacin 125 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 125 mg tienilic acid
Study: 373100
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg hydrochlorothiazide
Study: 6309204
Drug: suxamethonium 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: suxamethonium 10 mg
Study: 6309204
Drug: gallamine 20
Normalized name: gallamine 20 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: gallamine 20 mg
Study: 22409922
Drug: Honghua Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Honghua Injection
Study: 22409922
Drug: Control (routine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (routine Western medicine)
Study: 8695129
Drug: 0.25 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25 mg/kg mivacurium (divided dose: 0.15 mg/kg followed by 0.1 mg/kg after 30 seconds)
Study: 8695129
Drug: 1.5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 mg/kg succinylcholine (preceded by 50 micrograms/kg d‐tubocurarine)
Study: 8695129
Drug: 0.25 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25 mg/kg mivacurium (divided dose)
Study: 1524174
Drug: Infiltration with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infiltration with 4.4 ml of 1:80,000 adrenaline and 2% lignocaine
Study: 1524174
Drug: Moffett's solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moffett's solution containing 1 ml of 1:1,000 adrenaline
Study: 6500458
Drug: Metered dose
Normalized name: Metered Dose Inhaler
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metered dose inhaler with small expander
Study: 6500458
Drug: Metered dose
Normalized name: Metered Dose Inhaler
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metered dose inhaler with large expander
Study: 6500458
Drug: Metered dose
Normalized name: Metered Dose Inhaler
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metered dose inhaler without expander
Study: 29457512
Drug: Perceived network
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perceived network exposure to daily sugar-sweetened beverages
Study: 29457512
Drug: Perceived network
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perceived network exposure to daily sweets
Study: 29457512
Drug: Perceived network
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perceived network exposure to weekly vigorous exercise
Study: 29457512
Drug: Perceived network
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perceived network exposure to weekly moderate exercise
Study: 23123531
Drug: Hybrid treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hybrid treatment (4 weekly 2-hour sessions)
Study: 20209697
Drug: Sublingual misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sublingual misoprostol (400 microg every three hours, up to five doses)
Study: 20209697
Drug: Vaginal misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vaginal misoprostol (400 microg every three hours, up to five doses)
Study: 18722968
Drug: 10 mL
Normalized name: Vial Empty 10 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mL of 1% ropivacaine
Study: 18722968
Drug: 10 mL
Normalized name: Vial Empty 10 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mL of sterile water
Study: 16038172
Drug: Prophylaxis with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylaxis with omeprazole 40 mg and metoclopramide 10 mg in group A
Study: 16038172
Drug: Prophylaxis with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylaxis with omeprazole 40 mg and metoclopramide 10 mg in group B